(FP-01)-药物靶点：CD4 + CD8_专利_临床

概要

基本信息

药物类型

预防性疫苗

别名

Flunisyn、FP-01.1、FP 01

靶点

CD4 + CD8(T细胞表面抗原CD4 + 分化群8)

作用机制

CD4调节剂(T细胞表面抗原CD4调节剂)、CD8调节剂(分化群8调节剂)

治疗领域

感染、呼吸系统疾病

在研适应症-

非在研适应症

咳嗽、甲型流感病毒感染、流感病毒感染

原研机构

Altimmune, Inc.

在研机构-

非在研机构

Altimmune, Inc.

Immune Targeting Systems Ltd

Avalo Therapeutics, Inc.

最高研发状态(全球)终止临床2期

首次获批日期(全球)-

最高研发状态(中国)-

特殊审评-

关联

6

项与 FP-01 相关的临床试验

NCT01703923 / Completed临床2期

An Exploratory, Randomized, Placebo-Controlled, Double-Blind, Crossover Study of FP01 Lozenges in Subjects With Chronic Refractory Cough

The purpose of this study is to determine the antitussive effect size and dose response of FP01 lozenges in subjects with chronic cough and to demonstrate the safety and tolerability of FP01 lozenges in subjects with chronic cough.

开始日期2012-11-01

申办/合作机构

Avalo Therapeutics, Inc.

NCT01701752 / Completed临床1期

A Randomised, Double Blind, Double Observer Study to Assess Repeated Administration of a Single Dose of an Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Dose of a Trivalent Inactivated Influenza Virus Vaccine in Subjects 65 to 74 Years of Age.

This study will evaluate the safety and immunogenicity of FP-01.1 and FP-01.1 reformulated with an adjuvant (FP-01.1-Adjuvant) in relatively healthy subjects 65 to 74 years of age, subjects that are more representative of the target population. Both formulations will be administered alone or concomitantly with the Trivalent Inactivated Influenza Virus (TIV) vaccine.

开始日期2012-09-01

申办/合作机构

Immune Targeting Systems Ltd

NCT01597349 / Completed临床2期

An Exploratory, Randomized, Placebo Controlled, Double Blind, Parallel Arm Dose Ranging Study to Determine the Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection

The purpose of this research study is to learn how effective and safe FP01 lozenges are when given to subjects with a cough due to an upper respiratory tract infection. The study will include subjects who have an upper respiratory tract infection, with a cough of less than six weeks duration.

开始日期2012-05-01

申办/合作机构

Avalo Therapeutics, Inc.

100 项与 FP-01 相关的专利（医药）

登录后查看更多信息

15

项与 FP-01 相关的文献（医药）

2023-01-28·Viruses

Comparative Genomics of a Polyvalent Escherichia-Salmonella Phage fp01 and In Silico Analysis of Its Receptor Binding Protein and Conserved Enterobacteriaceae Phage Receptor.

Article

作者: Ignacio Vasquez ; Julio Retamales ; Barbara Parra ; Vimbai Machimbirike ; James Robeson ; Javier Santander

The polyvalent bacteriophage fp01, isolated from wastewater in Valparaiso, Chile, was described to have lytic activity across bacterial species, including Escherichia coli and Salmonella enterica serovars. Due to its polyvalent nature, the bacteriophage fp01 has potential applications in the biomedical, food and agricultural industries. Also, fundamental aspects of polyvalent bacteriophage biology are unknown. In this study, we sequenced and described the complete genome of the polyvalent phage fp01 (MH745368.2) using long- (MinION, Nanopore) and short-reads (MiSeq, Illumina) sequencing. The bacteriophage fp01 genome has 109,515 bp, double-stranded DNA with an average G+C content of 39%, and 158 coding sequences (CDSs). Phage fp01 has genes with high similarity to Escherichia coli, Salmonella enterica, and Shigella sp. phages. Phylogenetic analyses indicated that the phage fp01 is a new Tequintavirus fp01 specie. Receptor binding protein gp108 was identified as potentially responsible for fp01 polyvalent characteristics, which binds to conserved amino acid regions of the FhuA receptor of Enterobacteriaceae.

2023-01-04·Luminescence : the journal of biological and chemical luminescence

A highly sensitive ratiometric fluorescent probe based on fluorescein coumarin for detecting hydrazine in actual water and biological samples.

Article

作者: Linlin Lv ; Weiwei Luo ; Yixiao Zhou ; Tiechun Li ; Quanping Diao ; Pinyi Ma ; Daqian Song

Hydrazine (N₂ H₄ ) is a highly toxic and harmful chemical reagent. Fluorescent probes are simple and efficient tools for sensitive monitoring of N₂ H₄ enrichment in the environment, humans, animals and plants. In this work, a ratiometric fluorescent probe (FP-1) containing coumarin was used for hydrazine detection. The proposed FP-1 probe had a linear detection range of 0-250 μM and LOD of 0.059 μM (1.89 ppb). Large red Stokes shift was observed in fluorescence and UV-Vis absorption spectra, due to the hydrolysis of ester bonds between FP-1 and hydrazine. The hydrazine detection mechanism of FP-1 was also investigated by density functional theory (DFT) calculations. Finally, FP-1 could sensitively and selectively monitor hydrazine in actual water samples and BEAS-2B cells. Thus, it has great application potential in environmental monitoring and disease diagnosis.

2022-08-16·ACS Omega

Efficient Process for the Production of Alkyl Esters

Article

作者: Nagarkar, Rahul A. ; Nagabhushana, Kyatanahalli S. ; Chaudhari, Pankaj ; Mal, Nawal Kishor ; Dapurkar, Sudhir E.

This article reports a scalable process development for the production of alkyl esters through the esterification route by utilizing fly ash as a catalyst. The catalyst consisting of mixed oxides such as alumina, iron oxide, calcium oxide, magnesium oxide, and silica was employed for the esterification reaction without modification. The catalyst was evaluated for the conversion of feedstock containing variable amounts of free fatty acids, mono/dibasic acid, and alcohol/polyols into the corresponding alkyl esters. Three types of fly ash catalysts, viz., FS-1, FP-1, and FC-1, were chosen from three different industrial sources. Synthesis of dimethyl adipate was studied as a model reaction. FS-1 fly ash gave the highest yield of dimethyl adipate, whereas FC-1 gave a low yield of dimethyl adipate. The recyclability of FS-1 was evaluated for three cycles, and no loss of yield was observed. Furthermore, the catalyst FS-I was found to be capable of producing good yields for various esterification reactions with different substrates.

研发状态

适应症	最高研发状态	国家/地区	公司
甲型流感病毒感染	终止	英国更多	Altimmune, Inc. 更多
流感病毒感染	无进展	英国更多	Immune Targeting Systems Ltd 更多
咳嗽	无进展	美国更多	Avalo Therapeutics, Inc. 更多